EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)
- O Kowal-Bielecka1,
- R Landewé2,
- J Avouac3,
- S Chwiesko1,
- I Miniati4,
- L Czirjak5,
- P Clements6,
- C Denton7,
- D Farge8,
- K Fligelstone9,
- I Földvari10,
- D E Furst6,
- U Müller-Ladner11,
- J Seibold12,
- R M Silver13,
- K Takehara14,
- B Garay Toth15,
- A Tyndall16,
- G Valentini17,
- F van den Hoogen18,
- F Wigley19,
- F Zulian20,
- Marco Matucci-Cerinic4,
- and the EUSTAR co-authors
- 1Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland
- 2Department of Internal Medicine/Rheumatology, University Hospital Maastricht, Maastricht, The Netherlands
- 3Rheumatology A Department, RDU, Paris, France
- 4Department BioMedicine, Division of Rheumatology, University of Florence, Florence, Italy
- 5Rheumatology Department, UP, Pecs, Hungary
- 6Rheumatology Department, UCLA, Los Angeles, California, USA
- 7Rheumatology Department, RFH, London, UK
- 8Internal Medicine Department, HSL, Paris, France
- 9Scleroderma Association, FESCA, Harlesden, UK
- 10Department of Pediatric Rheumatology, Klin Eilbek, Hamburg, Germany
- 11Rheumatology Department, JLU, Bad Nauheim, Germany
- 12Rheumatology Department, UMI, Ann Arbor, Michigan, USA
- 13Rheumatology Department, MUSC, Charleston, Sorth Carolina, USA
- 14Dermatology Department, USM, Kanazawa, Japan
- 15Scleroderma Association, FESCA, Budapest, Hungary
- 16Rheumatology Department, UH, Basel, Switzerland
- 17Rheumatology Department, SU, Naples, Italy
- 18Rheumatology Centre Sint Maartenskliniek, Nijmegen, The Netherlands
- 19Rheumatology Department, JHU, Baltimore, Maryland, USA
- 20Department of Pediatrics, University of Padua, Padua, Italy
- Dr M Matucci-Cerinic, Department of BioMedicine and Surgery, Division of Rheumatology, University of Florence, Villa Monna Tessa, viale G Pieraccini 18, 50134 Florence, Italy; cerinic{at}unifi.it
- Accepted 10 December 2008
- Published Online First 15 January 2009
Abstract
Purpose: The optimal treatment of systemic sclerosis (SSc) is a challenge because the pathogenesis of SSc is unclear and it is an uncommon and clinically heterogeneous disease affecting multiple organ systems. The aim of the European League Against Rheumatism (EULAR) Scleroderma Trials and Research group (EUSTAR) was to develop evidence-based, consensus-derived recommendations for the treatment of SSc.
Methods: To obtain and maintain a high level of intrinsic quality and comparability of this approach, EULAR standard operating procedures were followed. The task force comprised 18 SSc experts from Europe, the USA and Japan, two SSc patients and three fellows for literature research. The preliminary set of research questions concerning SSc treatment was provided by 74 EUSTAR centres.
Results: Based on discussion of the clinical research evidence from published literature, and combining this with current expert opinion and clinical experience, 14 recommendations for the treatment of SSc were formulated. The final set includes the following recommendations: three on SSc-related digital vasculopathy (Raynaud’s phenomenon and ulcers); four on SSc-related pulmonary arterial hypertension; three on SSc-related gastrointestinal involvement; two on scleroderma renal crisis; one on SSc-related interstitial lung disease and one on skin involvement. Experts also formulated several questions for a future research agenda.
Conclusions: Evidence-based, consensus-derived recommendations are useful for rheumatologists to help guide treatment for patients with SSc. These recommendations may also help to define directions for future clinical research in SSc.
Footnotes
-
Competing interests: None.
-
Funding: This study received financial support from the European League Against Rheumatism.
-
‣ Additional supplementary material and tables 3 and 4 are published online only at http://ard.bmj.com/content/vol68/issue5
-
*EUSTAR co-authors: Lund (F Wollheim, A Scheja); Moskwa (T Nevskaya, L Ananieva, E Nassonov); Paris (Y Allanore, A Kahan); Lille (E Hachulla, D Launay); Manchester (A Herrick); Newcastle (J van Laar); Geneva (C Chizzolini); Bucharest (C Ciurtin, D Opris, R Ionescu, M Capraru); Cluj-Napoca (S Rednic); Zurich (O Distler); Ankara (I Simsek, A Dinc); Istanbul (M Inanc); Graz (W Graninger); Tubingen (I Kotter); Oslo (JT Gran, O Midvedt); Katowice (E Kucharz); Lublin (D Krasowska, M Majdan); Bialystok (S Sierakowski); Coimbra (MJ Salvador, JA Pereira da Silva); Belgrade (N Damjanov); Madrid (P Carreira, P Garcia de la Pena Lefebvre); Debrecen (G Szucs, ZSzekanecz); Praha (R Becvar); Porto (P Pinto); Lisbon (P Coelho); Rijeka (S Novak); Basle (U Walker); Dresden (M Aringer); Gottingen (T Glaenz, CH Neumann, S Emmert); Berlin (M Worm, G Riemekasten); Koln (T Krieg, N Hunzelmann); Mainz (K Steinbrink); Muenster (C Sunderkotter); Stuttgart (S Heitmann); Hamburg (I Foldvari); Bari (F Iannone, G Lapadula); Brescia (P Airň); L’Aquila (R Giacomelli); Milan (R Scorza); Genova (M Rizzi, F Indiveri); Rome (V Riccieri); Padova (F Zulian); Ljubljana (B Rozman); Tokyo (K Takehara); Seoul (Jae-Bum Jun); Philadalphia, (C Derk, N Sandorfi, S Jimenez); Johannesburg (M Tikly); Mosul (Saad Alhasani); Tel Hashomer (Y Shoenfeld); Haifa (A Balbir Gurmann).








